By Anthony O. Goriainoff
AstraZeneca PLC said Tuesday that Symbicort was approved in China as a treatment for mild asthma in patients over the age of 12.
The U.K. pharmaceutical giant said the approval by the National Medical Products Administration was based on the positive results of the SYGMA 1 and SYGMA 2 Phase 3 trials. Those evaluated the efficacy of Symbicort Turbuhaler taken, as needed, as an anti-inflammatory reliever compared with the standard of care therapies in mild asthma, the company said.
The company said Symbicort was already approved in China for patients with moderate to severe asthma.